| Drug General Information |
| Drug ID |
D02VKC
|
| Former ID |
DNC003508
|
| Drug Name |
NBQX
|
| Drug Type |
Small molecular drug
|
| Indication |
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89]
|
Phase 1 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H8N4O6S
|
| InChI |
InChI=1S/C12H8N4O6S/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22)
|
| InChIKey |
UQNAFPHGVPVTAL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
586260, 3153212, 4634329, 7980097, 9251954, 11113470, 14777739, 15397501, 26751693, 26759268, 34646396, 47216894, 47349363, 47662425, 50066260, 50251812, 53789223, 57356141, 72276108, 85245460, 85787793, 85788629, 91615359, 103509729, 109613894, 111881947, 118313821, 118508041, 125338989, 129406224, 134340713, 135061214, 135698079, 137009451, 137014386, 141003654, 142845642, 143245648, 143438594, 143552884, 152035117, 162022609, 162222865, 163687583, 164805409, 170539125, 178101081, 179293796, 223441583, 224912602
|
| Target and Pathway |
| Target(s) |
NMDA receptor subunit NR1 |
Target Info |
Inhibitor |
[2]
|
|---|
| Glutamate receptor, ionotropic kainate 1 |
Target Info |
Inhibitor |
[3]
|
| Glutamate receptor AMPA subtype |
Target Info |
Inhibitor |
[4]
|
| Glutamate [NMDA] receptor subunit epsilon 1 |
Target Info |
Inhibitor |
[2]
|
| Glutamate receptor 1 |
Target Info |
Inhibitor |
[5]
|
| Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
Glutamatergic synapsehsa04014:Ras signaling pathway
|
|
Dopaminergic synapse
|
|
Alcoholism
|
|
Systemic lupus erythematosushsa04024:cAMP signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Long-term depression
|
|
Nicotine addictionhsa04014:Ras signaling pathway
|
|
Systemic lupus erythematosus
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
|
|
Metabotropic glutamate receptor group I pathwayP00029:Huntington disease
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00037:Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathwayP00029:Huntington disease
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Pathway Interaction Database
|
Reelin signaling pathwayephbfwdpathway:EPHB forward signalingerbb4_pathway:ErbB4 signaling events
|
|
Reelin signaling pathway
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation
|
|
RAF/MAP kinase cascadeR-HSA-204005:COPII (Coat Protein 2) Mediated Vesicle Transport
|
|
Trafficking of AMPA receptors
|
|
Trafficking of GluR2-containing AMPA receptors
|
|
Cargo concentration in the ERR-HSA-3928662:EPHB-mediated forward signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Spinal Cord Injury
|
|
BDNF signaling pathway
|
|
Alzheimers DiseaseWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic CellWP666:Hypothetical Network for Drug Addiction
|
|
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
BDNF signaling pathwayWP666:Hypothetical Network for Drug Addiction
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4264). |
|---|
| REF 2 | J Med Chem. 2001 Sep 13;44(19):3157-65.Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173. |
|---|
| REF 3 | Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. |
|---|
| REF 4 | J Med Chem. 2007 Apr 5;50(7):1558-70. Epub 2007 Mar 10.Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. |
|---|
| REF 5 | J Med Chem. 2006 Oct 5;49(20):6015-26.Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies. |
|---|
